Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1995-06-07
1998-01-27
Jarvis, William R.A.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
A61K 31445
Patent
active
057122938
ABSTRACT:
Methods are disclosed utilizing the optically pure (-) isomer of norcisapride. This compound is a potent drug for the treatment of gastro-esophageal reflux disease, emesis, dyspepsia and other conditions while substantially reducing the concomitant liability of adverse effects associated with cisapride. The (-) isomer of norcisapride also avoids the adverse drug interactions associated with racemic cisapride and other therapeutic agents.
REFERENCES:
patent: 4962115 (1990-10-01), Van Daele
patent: 5057525 (1991-10-01), Van Daele
patent: 5137896 (1992-08-01), Van Daele
Gullikson, G.W., et al., "Relationship of Serotonin-3 Receptor Antagonist Activity to Gastric Emptying and Motor-Stimulating Actions of Prokinetic Drugs in Dogs," J. Pharmacol. Experimen. Therp., 258(1): 103-110 (1991).
Schapira, M., et al., "The Current Status of Gastric Prokinetic Drugs," Acta Gastro-Enterologica Belgica, 53:446-457 (1990).
Jamali, F., "Enantioselective Aspects of Drug Action and Disposition: Therapeutic Pitfalls, " Journal of Pharmaceutical Sciences, 78(9):695-715 (1989).
Nemeth, P.R., "Gastrointestinal motility stimulating drugs and 5-HT receptors or Myenteric Neurons," Eur. J. Pharmacol., 166:387-391 (1989).
Barone et al., "Bioavailability of Three Oral Dosage Forms of Cisapride, a Gastrointestinal Stimulant Agent," Clinical Pharmacy, 6:640-645 (1987).
Barnes, NM et al., "Identification of 5-HT.sub.3 Recognition Sites in the Ferret Area Postrema," J. Pharm. Pharmacol. 40:586-588 (1988).
Clarke, DE et al., "The 5-HT.sub.3 Receptor: Naughty, but Nice," Trends in Pharmacological Sciences 10:385-386 (1989).
Costall, B. et al., "Emesis Induced by Cisplatin in the Ferret as a Model for the Detection of Anti-Emetic Drugs," Neuropharmacology 26:1321-1326 (1987).
Craig & Clark, "5-Hydroxytryptamine and Cholinergic Mechanisms in Guinea-pig lleum," Brit. J. Pharmacol. 96:247 (1989).
Decktor, DL et al., "Effect of Metoclopramide, Bethanechol and the Cholecystokinin Receptor Antagonist, L-364, 718, on Gastric Emptying in the Rat," Eur. J. Pharmacol. 147:313-316 (1988).
Dumuis, A et al., "The Gastrointestinal Prokinetic Benzamide Derivatives are Agontist at the Non-Classical 5-HT Receptor (5-HT.sub.4 ) Positively Coupled to Adenylate Cyclase in Neurons, " N.S. Arch. Pharmacol. 340:403-410 (1989).
Fernandez & Massingham, "Peripheral Receptor Populations Involved in the Regulation of Gastrointestinal Motility and the Pharmacological Actions of Meoclopramide-like Drugs, " Life Sci. 36:1-14 (1985).
Frazer, A et al., "Subtypes of Receptors for Serotonin, " Annual Rev. of Pharmacology and Toxicology 30:307-348 (1990).
Gladziwa, U et al., "Pharmacokinetics and pharmacodynamics of cisapride in patients undergoing hemodialysis, " Clinical Pharmacology 50:6:673-681 (1991).
Krejs, GJ "Serotonine intestinale, une cible therapeutique," Med. Chir. Dig. 22:7:415-416 (1993).
Lauwers, W et al., "Identification of Biliary Metabolite of Cisapride," Biomedical and Environmental Mass Spectrometry 15:323-328 (1988).
Lavrijsen, K et al., "The Role of CYP3A4 in the In-Vitro Metabolism of Cisapride in Human Liver Microsomes and In-Vitro and In-Vivo Interactions of Cisapride with Co-Administered Drugs," Dept. of Pharmacokinetics and Drug Metabolism, Janssen Research Foundation, 1990.
Meuldermans, W et al.,"Excretion and Biotransformation of Cisapride in Dogs and Humans After Oral Administration" Drug Metabolism and Disposition 16:3:403-419 (1988).
Milo, R "Non-Cholinergic, Non-antidopaminergic Treatment of Chronic Digestive Symptoms Suggestive Of A Motility Disorder: A Two-Step Pilot Evaluation of Cisapride," Curr. Therapeutic Research 36:5:1053-1062 (1984).
Porsius, AJ et al., "Farmacotoets 6A," Farmacotherapie 129:9:214-217 (1994).
Reyntjens, A et al., "Clinical Pharmacological Evidence For Cisapride's Lack of Antidopaminergic or Direct Cholinergic Properties, " Current Therapeutic Research 36:5:1045-1052 (1984).
Schiavi, GB et al., "Identification of Serotonin 5-HT.sub.4 Recognition Sites in the Porcine Caudate Nucleus by Radioligand Binding," Neuropharmacology 33:543-549 (1994).
Schuurkes, JAJ et al., "Motor-Stimulating Properties of Cisapride on Isolated Gstrointestinal Preparations of the Guinea Pig." J. Pharmacol. Exp. Ther. 234 775-783 (1985).
Stacher, G et al., "Effects of Oral Cisapride on Interdigestive Jejunal Motor Activity, Psychomotor Function, and Side-Effect Profile in Healthy Man," Digestive Diseases and Sciences 32:11:1223-1230 (1987).
Van Peer, A et al., "Clinical Pharmacokinetics of Cisapride," Progress in the Treatment of Gastrointestinal Motility Disorders :The Role of Cisapride Proceedings of a Symposium in Frankfurt Excerpta Medica pp. 23-29 (1988).
Williams & Burks, "Cisapride Increases Gastric Emptying Without Affecting Small or Large Bowel Transit," Proc. West. Pharmacol. Soc. 28:47-50 (1985).
Zuccato, E et al., "The Effects of S(-) and R(+) Sulpiride, Metoclopramide, Cisapride and Domperidone on the Small Intestine Suggest DA.sub.2 Receptors are Involved in the Control of Small Intestinal Transit Time in Rats, " Pharmacological Research 26:2:179-185 (1992).
Scrip's New Product Review No. 32 Cisapride, PJB Publications Ltd. (Apr. 1989).
Nemeth et al., Chemical Abstracts, vol. 11, No. 19, abstract no. 167161a, 1989.
Gladziwa et al., Derwent Drug File Abstracts, abstract No. 91-32824, 1991.
Aberg A.K. Gunnar
McCullough John R.
Jarvis William R.A.
Sepracor Inc.
LandOfFree
Methods for treating gastro-esophageal reflux disease and other does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for treating gastro-esophageal reflux disease and other , we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for treating gastro-esophageal reflux disease and other will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-342704